Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline?

References

• Al-Hatmi AMS, Meis JF, de Hoog GS. Fusarium: molecular diversity and intrinsic drug resistance. PLoS Pathog. 2016;12(4):e1005464. doi:10.1371/journal.ppat.100546427054821
   PubMed Web of Science ®Google Scholar
• O’Donnell K, Rooney AP, Proctor RH, et al. Phylogenetic analyses of RPB1 and RPB2 support a middle cretaceous origin for a clade comprising all agriculturally and medically important fusaria. Fungal Genet Biol. 2013;52:20–31. doi:10.1016/j.fgb.2012.12.00423357352
   PubMed Web of Science ®Google Scholar
• O’Donnell K, Ward TJ, Robert VARG, Crous PW, Geiser DM, Kang S. DNA sequence-based identification of Fusarium: current status and future directions. Phytoparasitica. 2015;43:583–595. doi:10.1007/s12600-015-0484-z
   Web of Science ®Google Scholar
• Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev. 1994;7:479–504. doi:10.1128/CMR.7.4.4797834602
   PubMed Web of Science ®Google Scholar
• Dean R, Van Kan JA, Pretorius ZA, et al. The Top 10 fungal pathogens in molecular plant pathology. Mol Plant Pathol. 2012;13(4):414–430. doi:10.1111/j.1364-3703.2011.00783.x22471698
   PubMed Web of Science ®Google Scholar
• Sexton AC, Howlett BJ. Parallels in fungal pathogenesis on plant and animal hosts. Eukaryot Cell. 2006;5:1941–1949. doi:10.1128/EC.00277-0617041185
   PubMedGoogle Scholar
• Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695–704. doi:10.1128/CMR.00014-0717934079
   PubMed Web of Science ®Google Scholar
• De Hoog GS, Guarro J, Gené J, et al. Atlas of Clinical Fungi. 4th ed. Utrecht/Reus: Westerdijk Institute/Universitat Rovira i Virgili; 2019.
   Google Scholar
• Gauthier G, Keller N. Crossover fungal pathogens: the biology and pathogenesis of fungi capable of crossing kingdoms to infect plants and humans. Fungal Genet Biol. 2013;61:146–157. doi:10.1016/j.fgb.2013.08.01624021881
   PubMed Web of Science ®Google Scholar
• Schroers HJ, Samuels GJ, Zhang N, Short DP, Juba J, Geiser DM. Epitypification of Fusisporium (Fusarium) solani and its assignment to a common phylogenetic species in the Fusarium solani species complex. Mycologia. 2016;108(4):806–819. doi:10.3852/15-25527055573
   PubMed Web of Science ®Google Scholar
• Short DP, O’Donnell K, Thrane U, et al. Phylogenetic relationships among members of the Fusarium solani species complex in human infections and the descriptions of F. keratoplasticum sp. nov. and F. petroliphilum stat. nov. Fungal Genet Biol. 2013;53:59–70. doi:10.1016/j.fgb.2013.01.00423396261
   PubMed Web of Science ®Google Scholar
• Ortoneda M, Guarro J, Madrid MP, et al. Fusarium oxysporum as a multi-host model for the genetic dissection of fungal virulence in plants and mammals. Infect Immun. 2004;72(3):1760–1766. doi:10.1128/IAI.72.3.1760-1766.200414977985
   PubMed Web of Science ®Google Scholar
• Nalim FA, Samuels GJ, Wijesundera RL, Geiser DM. New species from the Fusarium solani species complex derived from perithecia and soil in the old World tropics. Mycologia. 2011;103(6):1302–1330. doi:10.3852/10-30721700636
   PubMed Web of Science ®Google Scholar
• Šišić A, Baćanović-Šišić J, Al-Hatmi AMS, et al. The ‘forma specialis’ issue in Fusarium: A case study in Fusarium solani f. sp. pisi. Sci Rep. 2018;8(1):1252. doi:10.1038/s41598-018-19779-z29352160
   PubMed Web of Science ®Google Scholar
• Mehl HL, Epstein L. Fusarium solani species complex isolates conspecific with Fusarium solani f. sp. cucurbitae race 2 from naturally infected human and plant tissue and environmental sources are equally virulent on plants, grow at 37 degrees C and are interfertile. Environ Microbiol. 2007;9(9):2189–2199. doi:10.1111/j.1462-2920.2007.01333.x17686017
   PubMed Web of Science ®Google Scholar
• Zhang N, O’Donnell K, Sutton DA, et al. Members of the Fusarium solani species complex that cause infections in both humans and plants are common in the environment. J Clin Microbiol. 2006;44(6):2186–2190. doi:10.1128/JCM.00120-0616757619
   PubMed Web of Science ®Google Scholar
• Edwards ET. Studies on the Gibberella fujikuroi var. subglutinans the hitherto undescribed ascigerous stage of Fusarium moniliforme var. subglutinans and its pathogenicity on maize in New South Wales. Dep Agric New South Wales Sci Bull. 1935;49:1–68.
   Google Scholar
• Schäfer K, Di Pietro A, Gow NA, MacCallum D. Murine model for Fusarium oxysporum invasive fusariosis reveals organ-specific structures for dissemination and long-term persistence. PLoS One. 2014;9(2):e89920. doi:10.1371/journal.pone.008992024587124
   PubMed Web of Science ®Google Scholar
• Al-Hatmi AM, Bonifaz A, de Hoog GS, et al. Keratitis by Fusarium temperatum, a novel opportunist. BMC Infect Dis. 2014;14:588. doi:10.1186/s12879-014-0588-y25388601
   PubMed Web of Science ®Google Scholar
• Boral H, van Diepeningen A, Erdem E, et al. Mycotic keratitis caused by Fusarium solani sensu stricto (FSSC5): a case series. Mycopathologia. 2018;183:835–840. doi:10.1007/s11046-018-0280-729931660
   PubMed Web of Science ®Google Scholar
• Al-Hatmi AMS, Sandoval-Denis M, Nabet C, et al. Fusarium volatile, a new potential pathogen from a human respiratory sample. Fungal Syst Evol. 2019;4:71–181. doi:10.3114/fuse.2019.04.09
   Google Scholar
• Ma LJ, van der Does HC, Borkovich KA, et al. Comparative genomics reveals mobile pathogenicity chromosomes in Fusarium. Nature. 2010;464:367–373. doi:10.1038/nature0885020237561
   PubMed Web of Science ®Google Scholar
• Vlaardingerbroek I, Beerens B, Rose L, et al. Exchange of core chromosomes and horizontal transfer of lineage‐specific chromosomes in Fusarium oxysporum. Environm Microbiol. 2016;18:3702–3713. doi:10.1111/1462-2920.13281
   Web of Science ®Google Scholar
• Perez-Nadales E, Di Pietro A. The membrane mucin Msb2 regulates invasive growth and plant infection in Fusarium oxysporum. Plant Cell. 2011;23:1171–1185. doi:10.1105/tpc.110.07509321441438
   PubMed Web of Science ®Google Scholar
• Segorbe D, Di Pietro A, Perez-Nadales E, Turra D. Three Fusarium oxysporum mitogen-activated protein kinases (MAPKs) have distinct and complementary roles in stress adaptation and cross-kingdom pathogenicity. Mol Plant Pathol. 2017;18(7):912–924. doi:10.1111/mpp.2017.18.issue-727301316
   PubMed Web of Science ®Google Scholar
• Van Baarlen P, Van Belkum A, Summerbell R, Crous PW, Thomma B. Molecular mechanisms of pathogenicity: how do pathogenic microorganisms develop cross-kingdom host jumps? FEMS Microbiol Rev. 2007;31:239–277. doi:10.1111/j.1574-6976.2007.00065.x17326816
   PubMed Web of Science ®Google Scholar
• Gostincar C, Zajc J, Lenassi M, et al. Fungi between extremotolerance and opportunistic pathogenicity on humans. Fungal Divers. 2018;93:195–213. doi:10.1007/s13225-018-0414-8
   Web of Science ®Google Scholar
• Navarro-Velasco GY, Prados-Rosales RC, Ortíz-Urquiza A, Quesada-Moraga E, Di Pietro A. Galleria mellonella as model host for the trans-kingdom pathogen Fusarium oxysporum. Fungal Genet Biol. 2011;48(12):1124–1129. doi:10.1016/j.fgb.2011.08.00421907298
   PubMed Web of Science ®Google Scholar
• Moretti ML, Busso-Lopes AF, Tararam CA, et al. Airborne transmission of invasive fusariosis in patients with hematologic malignancies. PLoS One. 2018;13:e0196426. doi:10.1371/journal.pone.019642629698435
   PubMed Web of Science ®Google Scholar
• Nucci M, Shoham S, Abdala E, et al. Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis? Mycoses. 2019;62(5):413–417. doi:10.1111/myc.2019.62.issue-530720902
   PubMed Web of Science ®Google Scholar
• Wickern GM. Fusarium allergic fungal sinusitis. J Allergy Clin Immunol. 1993;92:624–625. doi:10.1016/0091-6749(93)90087-V8409122
   PubMed Web of Science ®Google Scholar
• van Diepeningen AD, Feng P, Ahmed S, et al. Spectrum of Fusarium infections in tropical dermatology evidenced by multilocus sequencing typing diagnostics. Mycoses. 2015;58:48–57. doi:10.1111/myc.1227325530264
   PubMed Web of Science ®Google Scholar
• Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13. doi:10.1126/scitranslmed.3004404
   PubMed Web of Science ®Google Scholar
• Leslie JF, Summerell BA. The Fusarium Laboratory Manual. Ames, IA: Blackwell Publishing; 2006.
   Google Scholar
• Apple O, Wollenweber HW. Grundlagen einer Monographie der Gattung Fusarium (Link). In Arb K Biol Anst F Land U Forstw. 1910;8:1–207.
   Google Scholar
• Wollenweber HW, Reinking OA. The Fusaria: Their Description Injurious Effects and Control. Vol. 8 Berlin: Paul Parey; 1935:1–135.
   Google Scholar
• Booth C. The Genus Fusarium. Kew: Commonwealth Mycological Institute; 1971:237.
   Google Scholar
• Gerlach W, Nirenberg H. The genus Fusarium-a pictorial atlas. Mitt Biol Bundes Anst Land- Forstw. 1982;209:1–406.
   Google Scholar
• Chen M, Zeng J, De Hoog GS, et al. The “species complex” issue in clinically relevant fungi: a case study in Scedosporium apiospermum. Fungal Biol. 2016;120:137–146. doi:10.1016/j.funbio.2015.09.00326781369
   PubMed Web of Science ®Google Scholar
• Kwon-Chung KJ, Bennett JE, Wickes BL, et al. The case for adopting the “species complex” nomenclature for the etiologic agents of cryptococcosis. mSphere. 2017;2:e00357–16. doi:10.1128/mSphere.00357-16
   PubMed Web of Science ®Google Scholar
• Geiser DM, Aoki T, Bacon CW, et al. One fungus, one name: defining the genus Fusarium in a scientifically robust way that preserves longstanding use. Phytopathology. 2013;103:400–408. doi:10.1094/PHYTO-07-12-0150-LE23379853
   PubMed Web of Science ®Google Scholar
• Lombard L, van der Merwe NA, Groenewald JZ, Crous PW. Generic concepts in Nectriaceae. Stud Mycol. 2015;80:189–245. doi:10.1016/j.simyco.2014.12.00226955195
   PubMed Web of Science ®Google Scholar
• Sandoval-Denis M, Lombard L, Crous PW. Back to the roots: a reappraisal of Neocosmospora. Persoonia. 2019;43:90–185.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013;9(10):e1003633. doi:10.1371/journal.ppat.100363324204249
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Meis JF. Emergence of azole resistant Aspergillus fumigatus and One Health: time to implement environmental stewardship. Environ Microbiol. 2018;20(4):1299–1301. doi:10.1111/emi.2018.20.issue-429393565
   PubMed Web of Science ®Google Scholar
• Alvarez-Moreno C, Lavergne RA, Hagen F, Morio F, Meis JF, Le Pape P. Fungicide-driven alterations in azole-resistant Aspergillus fumigatus are related to vegetable crops in Colombia, South America. Mycologia. 2019;111(2):217–224. doi:10.1080/00275514.2018.155779630896313
   PubMed Web of Science ®Google Scholar
• Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc Lond B Biol Sci. 2016;371(1709):20150460. doi:10.1098/rstb.2015.046028080986
   PubMed Web of Science ®Google Scholar
• Herkert PF, Al-Hatmi AMS, De Oliveira Salvador GL, et al. Molecular characterization and antifungal susceptibility of clinical Fusarium species from Brazil. Front Microbiol. 2019;10:737. doi:10.3389/fmicb.2019.0073731024507
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017;10:249–259. doi:10.2147/IDR.S12491828919789
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10(Suppl 1):48–66. doi:10.1111/j.1470-9465.2004.00839.x14748802
   PubMed Web of Science ®Google Scholar
• Lackner M, Hagen F, Meis JF, et al. Susceptibility and diversity in the therapy-refractory genus Scedosporium. Antimicrob Agents Chemother. 2014;58(10):5877–5885. doi:10.1128/AAC.03211-1425070092
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Prakash A, Sharma C, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73(4):891–899. doi:10.1093/jac/dkx48029325167
   PubMed Web of Science ®Google Scholar
• Al-Hatmi AMS, Bonifaz A, Ranque S, De Hoog GS, Verweij PE, Meis JF. Current antifungal treatment of fusariosis. Int J Antimicrob Agents. 2018;51(3):326–332. doi:10.1016/j.ijantimicag.2017.06.01728705676
   PubMed Web of Science ®Google Scholar
• Scorzoni L, Silva ACAP, Marcos CM, et al. Antifungal therapy: new advances in the understanding and treatment of mycosis. Front Microbiol. 2017;8:1–23.28197127
   PubMed Web of Science ®Google Scholar
• Fan J, Urban M, Parker JE, et al. Characterization of the sterol 14α-demethylases of Fusarium graminearum identifies a novel genus-specific CYP51 function. New Phytol. 2013;198:821–835. doi:10.1111/nph.1219323442154
   PubMed Web of Science ®Google Scholar
• Katiyar SK, Edlind TD. Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 2009;53(5):1772–1778. doi:10.1128/AAC.00020-0919258277
   PubMed Web of Science ®Google Scholar
• Cannon RD, Lamping E, Holmes AR, et al. Efflux-mediated antifungal drug resistance. Clin Microbiol Rev. 2009;22:291–321. doi:10.1128/CMR.00051-0819366916
   PubMed Web of Science ®Google Scholar
• Becher R, Weihmann F, Deising HB, Wirsel SG. Development of a novel multiplex DNA microarray for Fusarium graminearum and analysis of azole fungicide responses. BMC Genomics. 2011;12:52. doi:10.1186/1471-2164-12-5221255412
   PubMed Web of Science ®Google Scholar
• Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother. 1997;41:535–539. doi:10.1128/AAC.41.3.5359055988
   PubMed Web of Science ®Google Scholar
• Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother. 2009;53:2804–2815. doi:10.1128/AAC.00295-0919414582
   PubMed Web of Science ®Google Scholar
• Tobin MB, Peery RB, Skatrud PL. Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus. Gene. 1997;200:11–23. doi:10.1016/S0378-1119(97)00281-39373135
   PubMed Web of Science ®Google Scholar
• Mellado E, Garcia-Effron G, Alcázar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897–1904. doi:10.1128/AAC.01092-0617371828
   PubMed Web of Science ®Google Scholar
• Diaz-Trujillo C, da Cunha C, Chong P, Etienne Duveiller and Pawan K. Singh et al. Azole resistance is related to overexpression of the CYP51 gene in Mycosphaerella fijiensis In: Book of Abstracts EPS PhD Autumn School ‘host-Microbe Interactomics’. the Netherlands: Wageningen; 2011:26–27.
   Google Scholar
• Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997;41:1364–1368. doi:10.1128/AAC.41.6.13649174200
   PubMed Web of Science ®Google Scholar
• Snelders E, Rijs AJ, Kema GH, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75:4053–4057. doi:10.1128/AEM.00231-0919376899
   PubMed Web of Science ®Google Scholar
• Lucas JA, Hawkins NJ, Fraaije BA. The evolution of fungicide resistance. Adv Appl Microbiol. 2015;90:29–92.25596029
   PubMed Web of Science ®Google Scholar
• Kretschmer M, Leroch M, Mosbach A, et al. Fungicide-driven evolution and molecular basis of multidrug resistance in field populations of the grey mould fungus Botrytis cinerea. PLoS Pathog. 2009;5(12):e1000696. doi:10.1371/journal.ppat.100069620019793
   PubMed Web of Science ®Google Scholar
• Mouches C, Pasteur N, Berge JB, et al. Amplification of an esterase gene is responsible for insecticide resistance in a Californian Culex mosquito. Science. 1986;233:778–780. doi:10.1126/science.37555463755546
   PubMed Web of Science ®Google Scholar
• Verweij PE, Snelders E, Kema GHJ, Mellado E, Melchers WGJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009;9:789–795. doi:10.1016/S1473-3099(09)70265-819926038
   PubMed Web of Science ®Google Scholar
• Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, de Hoog GS, Meis JF. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother. 2015;70:1068–1071. doi:10.1093/jac/dku50525538167
   PubMed Web of Science ®Google Scholar
• Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev. 2003;16:730–797. doi:10.1128/CMR.16.4.730-797.200314557297
   PubMed Web of Science ®Google Scholar
• Qiu S, Zhao GQ, Lin J, et al. Natamycin in the treatment of fungal keratitis: a systematic review and meta-analysis. Int J Ophthalmol. 2015;8(3):597–602. doi:10.3980/j.issn.2222-3959.2015.03.2926086015
   PubMed Web of Science ®Google Scholar
• Oliveira Dos Santos C, Kolwijck E, van der Lee HA, et al. In vitro activity of chlorhexidine compared with seven antifungal agents against 98 Fusarium isolates recovered from fungal keratitis patients. Antimicrob Agents Chemother. 2019;63(8):e02669–18. doi:10.1128/AAC.02669-1831182529
   PubMed Web of Science ®Google Scholar
• Kunt Z, Yağmur M, Kandemir H, et al. In vitro efficacy of chlorhexidine and a riboflavin/UVA combination on fungal agents of keratitis. Curr Eye Res. 2019;14:1–5. doi:10.1080/02713683.2019.1652916
   Web of Science ®Google Scholar
• Todokoro D, Suzuki T, Tamura T, et al. Efficacy of luliconazole against broad-range filamentous fungi including Fusarium solani species complex causing fungal keratitis. Cornea. 2019;38(2):238–242. doi:10.1097/ICO.000000000000181230422866
   PubMed Web of Science ®Google Scholar
• Al-Hatmi AM, Meletiadis J, Curfs-Breuker I, Bonifaz A, Meis JF, De Hoog GS. In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis. J Antimicrob Chemother. 2016;71:953–955. doi:10.1093/jac/dkv42126702918
   PubMed Web of Science ®Google Scholar
• Prajna NV, Krishnan T, Mascarenhas J, et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs. voriconazole. JAMA Ophthalmol. 2013;131:422–429. doi:10.1001/jamaophthalmol.2013.149723710492
   PubMed Web of Science ®Google Scholar
• Rees CA, Bao B, Zegans ME, Cramera RA. Natamycin and voriconazole exhibit synergistic interactions with nonantifungal ophthalmic agents against Fusarium species ocular isolates. Antimicrob Agents Chemother. 2019;63:e02505–18. doi:10.1128/AAC.02505-1831010869
   PubMed Web of Science ®Google Scholar
• Varon AG, Nouer SA, Barreiros G, et al. Superficial skin lesions positive for Fusarium are associated with subsequent development of invasive fusariosis. J Infect. 2014;68:85–89. doi:10.1016/j.jinf.2013.08.01123994063
   PubMed Web of Science ®Google Scholar
• Galletti J, Negri M, Grassi FL, Kioshima-Cotica ÉS, Svidzinski TI. Fusarium spp. is able to grow and invade healthy human nails as a single source of nutrients. Eur J Clin Microbiol Infect Dis. 2015;34:1767–1772. doi:10.1007/s10096-015-2410-126007318
   PubMed Web of Science ®Google Scholar
• Tupaki-Sreepurna A, Jishnu BT, Thanneru V, et al. An assessment of in vitro antifungal activities of efinaconazole and itraconazole against common non-dermatophyte fungi causing onychomycosis. J Fungi. 2017;3(2):E20. doi:10.3390/jof3020020
   Web of Science ®Google Scholar
• Sahni K, Singh S, Dogra S. Newer topical treatments in skin and nail dermatophyte infections. Indian Dermatol Online J. 2018;9(3):149–158. doi:10.4103/idoj.IDOJ_281_1729854633
   PubMedGoogle Scholar
• Abastabar M, Al-Hatmi AMS, Vafaei Moghaddam M, et al. Potent activity of luliconazole, lanoconazole and eight comparators against molecularly characterized Fusarium species. Antimicrob Agents Chemother. 2018;62(5):e00009–18. doi:10.1128/AAC.00009-1829530844
   PubMed Web of Science ®Google Scholar
• Ortoneda M, Capilla J, Pastor FJ, Pujol I, Guarro J. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother. 2002;46:2273–2275. doi:10.1128/AAC.46.7.2273-2275.200212069988
   PubMed Web of Science ®Google Scholar
• Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163–174. doi:10.2147/IDR.S5134024187505
   PubMedGoogle Scholar
• Cornely OA, Ostrosky-Zeichner L, Rahav G, et al. Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp. treated with isavuconazole: experience from the VITAL and SECURE trials. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM Washington, DC, USA, 5–9 9 2014 (Abstract no. M-1760).
   Google Scholar
• Marty FM, Cornely OA, Mullane KM, et al. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses. 2018;61(7):485–497. doi:10.1111/myc.2018.61.issue-729611227
   PubMed Web of Science ®Google Scholar
• Nakamura I, Yoshimura S, Masaki T, et al. ASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833. J Antibiot (Tokyo). 2017;70(1):45–51. doi:10.1038/ja.2016.10727599768
   PubMed Web of Science ®Google Scholar
• Koselny K, Green J, DiDone L, et al. The celecoxib derivative AR-12 has broad spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis. Antimicrob Agents Chemother. 2016;60:7115–7127. doi:10.1128/AAC.01061-1627645246
   PubMed Web of Science ®Google Scholar
• Koselny K, Green J, Favazzo L, et al. Antitumor/antifungal celecoxib derivative AR-12 is a non-nucleoside inhibitor of the ANL-family adenylating enzyme acetyl CoA synthetase. ACS Infect Dis. 2016;2(4):268–280. doi:10.1021/acsinfecdis.5b0013427088128
   PubMed Web of Science ®Google Scholar
• Oliver JD, Sibley GE, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci U S A. 2016;113(45):12809–12814. doi:10.1073/pnas.160830411327791100
   PubMed Web of Science ®Google Scholar
• Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16(9):603–616. doi:10.1038/nrd.2017.4628496146
   PubMed Web of Science ®Google Scholar
• Jørgensen KM, Astvad KMT, Hare RK, Arendrup MC. EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs. Antimicrob Agents Chemother. 2018;62:e00487–18. doi:10.1128/AAC.00487-1829784842
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55:4652–4658. doi:10.1128/AAC.00291-1121825291
   PubMed Web of Science ®Google Scholar
• Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother. 2012;56(1):352–357. doi:10.1128/AAC.05414-1122083469
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. Activity of MK-3118, a new oral glucan synthase inhibitor tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother. 2013;68:858–863. doi:10.1093/jac/dks46623190764
   PubMed Web of Science ®Google Scholar
• Lamoth F, Alexander BD. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother. 2015;59:4308–4311. doi:10.1128/AAC.00234-1525896696
   PubMed Web of Science ®Google Scholar
• Mitsuyama J, Nomura N, Hashimoto K, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008;52(4):1318–1324. doi:10.1128/AAC.01159-0718227186
   PubMed Web of Science ®Google Scholar
• Shibata T, Takahashi T, Yamada E, et al. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother. 2012;56:5892–5897. doi:10.1128/AAC.05954-1122948882
   PubMed Web of Science ®Google Scholar
• Pianalto KM, Alspaugh JA. New horizons in antifungal therapy. J Fungi. 2016;2(4):E26. doi:10.3390/jof2040026
   Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009;47:3797–3804. doi:10.1128/JCM.00618-0919794038
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Rhomberg PR, Messer SA, Castanheira M. In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. Diagn Microbiol Infect Dis. 2015;81:259–263. doi:10.1016/j.diagmicrobio.2014.11.00825600842
   PubMed Web of Science ®Google Scholar